origanum majorana goutte 4ch-30ch drops
dolisos laboratoires s.a. - origanum majorana - drops - 1dh - origanum majorana 1dh - homeopathic products
origanum majorana globules
dolisos canada inc. - origanum majorana - globules - 1x - origanum majorana 1x - homeopathic products
alunbrig- brigatinib tablet, coated
ariad pharmaceuticals inc. - brigatinib (unii: hyw8db273j) (brigatinib - unii:hyw8db273j) - brigatinib 30 mg - alunbrig is indicated for the treatment of patients with anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc) who have progressed on or are intolerant to crizotinib. this indication is approved under accelerated approval based on tumor response rate and duration of response [see clinical studies (14)] . continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. none. risk summary based on its mechanism of action and findings in animals, alunbrig can cause fetal harm when administered to a pregnant woman [see data and clinical pharmacology (12.1)] . there are no clinical data on the use of alunbrig in pregnant women. administration of brigatinib to pregnant rats during the period of organogenesis resulted in dose-related skeletal anomalies at doses as low as 12.5 mg/kg/day (approximately 0.7 times the human exposure by auc at 180 mg once daily) as well as increased post-implantation loss, malformatio
alunbrig- brigatinib tablet, film coated alunbrig- brigatinib kit
takeda pharmaceuticals america, inc. - brigatinib (unii: hyw8db273j) (brigatinib - unii:hyw8db273j) - brigatinib 30 mg - alunbrig is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc) as detected by an fda-approved test [see dosage and administration (2.1)] . none. risk summary based on its mechanism of action and findings in animals, alunbrig can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no clinical data on the use of alunbrig in pregnant women. administration of brigatinib to pregnant rats during the period of organogenesis resulted in dose-related skeletal anomalies at doses as low as 12.5 mg/kg/day (approximately 0.7 times the human exposure by auc at 180 mg once daily) as well as increased post-implantation loss, malformations, and decreased fetal body weight at doses of 25 mg/kg/day (approximately 1.26 times the human exposure at 180 mg once daily) or greater (see data) . advise pregnant women of the potential risk to a fetus. in the u.s. general population, the estimated back
origanum majorana pellet
washington homeopathic products - origanum - to relieve the symptoms of impulsiveness. indications: origanum impulsiveness if symptoms persist/worsen or if pregnant/nursing, stop use and consult your practitioner.
origanum majorana liquid
washington homeopathic products - origanum - to relieve the symptoms of impulsiveness. indications: origanum impulsiveness if symptoms persist/worsen or if pregnant/nursing, consult your practitioner.
alunbrig (brigatinib) 30mg film-coated tablet
takeda malaysia sdn bhd - brigatinib -
alunbrig (brigatinib) 180mg film-coated tablet
takeda malaysia sdn bhd - brigatinib -
alunbrig (brigatinib) 90mg film-coated tablet
takeda malaysia sdn bhd - brigatinib -
bridgewest chlorhexidine 0.2% catheter prep irrigation solution ampoule
bridgewest perth pharma pty ltd - chlorhexidine gluconate, quantity: 60 mg - solution, irrigation - excipient ingredients: methylene blue; water for injections; sodium hydroxide; gluconic acid - for antisepsis of external genitalia prior to catheterisation of the bladder.